中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2012, Vol. 47 Issue (17) :1350-1356    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
����֬��������������֬���������֬�����׸�ҩϵͳ�ıȽ�
��ϼ��������*
������ҽѧԺҩѧԺ������ʡ�ߵ�ѧУʡ���ִ���ҩ�ص�ʵ���ң��Ϸ� 230038)

Download: PDF (0KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ��������֬��������������֬������������ԡ�ҩ���ͷš�Ӧ������ȷ����о���չ������ ���Ĺ�����������ס��������� �Թ���֬��Ϊ���ʲ��ϵ���������ϵͳ��������֬��������������Ҫ�������������Եĸ��۵�֬��Ϊ�Ǽܲ����Ƴɵ��ڳ����³ʹ�����������ӣ�������֬��������ı��˹���֬������������֬�ʵĹ��ɣ����ÿռ��ϲ����ݵĻ��֬�ʣ�������Һ��֬�ʣ�Ϊ��������Ʊ����ɵľ�������ṹ����������ϵͳ�������˹���֬���������෽��DZ�ڵ�ȱ�ݡ����߾��ж෽�����ͬ�㣬��Ƚ��о�����㷺��
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
��ϼ
������
�ؼ����� ����֬��������   ����֬������   ֬�����׸�ҩϵͳ     
Abstract��
Keywords��   
�ո�����: 2012-09-12;
ͨѶ���� ��ϼ��Ů��˶ʿ�о��� �о�����ҩ���¼��ͼ�ҩ�ﶯ��ѧ ��ͨѶ���߳��������У����ڣ���ʿ��˶ʿ����ʦ �о�������ҩ�з���ҩ�ﶯ��ѧ Tel��0551��5136810 E-mailanzhongdong@126.com     Email: anzhongdong@126.com
���ñ���:   
��ϼ, ������ .����֬��������������֬���������֬�����׸�ҩϵͳ�ıȽ�[J]  �й�ҩѧ��־, 2012,V47(17): 1350-1356
HUANG Xia, CHEN Wei-Dong-* .[J]  Chinese Pharmaceutical Journal, 2012,V47(17): 1350-1356
��
[1] MULLER R H�� MADER K�� GOHLA S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art [J]. Eur J Pharm Biopharm�� 2000�� 50(1)��161-177.
[2] MULLER R H�� RADTKE M�� WISSING S A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers(NLC) in cosmetic and dermatological preparations[J]. Adv Drug Deliv Rev�� 2002�� 54(1)��131-155.
[3] WISSING S A�� KAYSER O�� MULLER R H. Solid lipid nanoparticles for parenteral drug delivery [J]. Adv Drug Deliv Rev�� 2004�� 56(9)��1257- 1272.
[4] MULLER R H�� RADTKE M�� WISSING S A. Nanostructured lipid matrices for improved microencapsulation of drugs[J]. Int J Pharm�� 2002�� 242(1-2)��121-128.
[5] SCHAFER-KORTING M�� MEHNERT W�� KORTING H C. Lipid nanoparticles for improved topical application of drugs for skin diseases[J]. Adv Drug Deliv Rev�� 2007��59(6)��427-443.
[6] ATTAMA A A�� SCHICKE B C�� MULLER-GOYMANN C C. Further characterization of theobroma oil-beeswax admixtures as lipid matrices for improved drug delivery systems[J]. Eur J Pharm Biopharm�� 2006�� 64(3)��294-306.
[7] DAS S�� CHAUDHURY A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery [J]. AAPS Pharm Sci Tech�� 2011�� 12(1)��62-76.
[8] GRAMDORF S�� HERMNN S�� HENTSCHEL A�� et al. Crystallized miniemulsions��Influence of operating parameters during high-pressure homogenization on size and shape of particles [J]. Colloids Surf A��Physicochem Eng Aspects�� 2008�� 331(1-2)��108-113.
[9] HUNG L C�� BASRI M�� TEJO B A�� et al. An improved method for the preparations of nanostructured lipid carriers containing heat-sensitive bioactives[J]. Colloids Surf B Biointerfaces�� 2011�� 87(1)��180- 186.
[10] DOKTOROVOVA S�� ARAUJO J�� GARCIA M L�� et al. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC)[J]. Colloids Surf B Biointerfaces�� 2010�� 75(2)��538-542.
[11] PATHAK P�� NAGARSENKER M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery [J]. AAPS Pharm Sci Tech�� 2009�� 10(3)��985-992.
[12] LIU C H�� WU C T. Optimization of nanostructured lipid carriers for lutein delivery [J]. Colloids Surf A��Physicochem Eng Aspects�� 2010�� 353(2-3) ��149-156.
[13] LIU D F�� JIANG S M�� SHEN H�� et al. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method[J]. J Nanopart Res�� 2011�� 13(6)��2375-2386.
[14] TIWARI R�� PATHAK K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin��Comparative analysis of characteristics�� pharmacokinetics and tissue uptake [J]. Int J Pharm�� 2011�� 415(1-2)��232-243.
[15] DAI W T�� ZHANG D R�� DUAN C X�� et al. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system[J]. J Microencapsul�� 2010�� 27(3)��234-241.
[16] ZHANG S H�� YUN J X�� SHEN S C�� et al. Formation of solid lipid nanoparticles in a microchannel system with a cross-shaped junction[J]. Chem Eng Sci�� 2008�� 63(23)��5600-5605.
[17] YUN J X�� ZHANG S H�� SHEN S C�� et al. Continuous production of solid lipid nanoparticles by liquid flow-focusing and gas displacing method in microchannels[J]. Chem Eng Sci�� 2009�� 64(19)��4115-4122.
[18] CHEN C C��TSAI T H�� HUANG Z R��et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers��Physicochemical characterization and pharmacokinetics [J]. Eur J Pharm Biopharm�� 2010�� 74(3)��474-482.
[19] SANAD R A�� ABDELMALAK N S�� ELBAYOOMY T S�� et al. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers(NLCs)[J]. AAPS Pharm Sci Tech�� 2010�� 11(4)��1684-1694.
[20] TEERANACHAIDEEKUL V�� BOONME P�� SOUTO E B�� et al. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC[J]. J Controlled Release�� 2008�� 128(2)��134-141.
[21] HU F Q�� JIANG S P�� DU Y Z�� et al . Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system[J]. Colloids Surf B Biointerfaces��2005��45(3-4)��167-173.
[22] ATTAMA A A�� SCHICKE B C�� PAEPENMULLER T�� et al. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid��Characterization[J]. Eur J Pharm Biopharm�� 2007�� 67(1)��48-57.
[23] YUAN H�� WANG L L�� DU Y Z��et al. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification [J]. Colloids Surf B Biointerfaces�� 2007�� 60(2)��174-179.
[24] BAYINDIR Z S�� YUKSEL N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery [J]. J Pharm Sci�� 2010�� 99(4)��2049-2060.
[25] SEVERINO P�� PINHO S C�� SOUTO E B��et al. Crystallinity of Dynasan-114 and Dynasan-118 matrices for the production of stable Miglyol-loaded nanoparticles[J]. J Therm Anal Calorim�� 2010�� 108��1����101-108.
[26] RUKTANONCHAI U�� BEJRAPHA P�� SAKULKHU U�� et al. Physicochemical characteristics�� cytotoxicity�� and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid[J]. AAPS Pharm Sci Tech�� 2009�� 10(1)��227-234.
[27] LI Z��YU L�� ZHENG L Q�� et al. Studies on crystallinity state of puerarin loaded solid lipid nanoparticles prepared by double emulsion method[J]. J Therm Anal Calorim�� 2010�� 99(2)��689-693.
[28] TEERANACHAIDEEKUL V�� SOUTO E B�� JUNVAPRASERT V B��et al. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - Development�� physicochemical characterization and in vitro release studies[J]. Eur J Pharm Biopharm�� 2007�� 67(1)��141-148.
[29] CASTELLI F�� PUGLIA C�� SARPIETRO M G�� et al. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry[J]. Int J Pharm�� 2005�� 304(1-2)��231-238.
[30] JORES K�� MEHNERT W�� DRECHSLER M��et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy�� field-flow fractionation and transmission electron microscopy[J]. J Controlled Release�� 2004��95(2)��217- 227.
[31] JORES K�� HABERLAND A�� WARTEWIG S��et al. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by Spectrofluorometry and Raman Spectroscopy[J]. Pharm Res�� 2005�� 22(11)��1887-1897.
[32] SAUPE A�� GORDON K C�� RADES T . Structural investigations on nanoemulsions�� solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy[J]. Int J Pharm�� 2006�� 314(1)��56-62.
[33] MULLER R H�� PETERSEN R D�� HOMMOSS A��et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products[J]. Adv Drug Deliv Rev�� 2007�� 59(6)��522-530.
[34] JENNINGV��THUNEMANN A F��GOHLA S H. Charaterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids[J ]. Int J Pharm�� 2000��199 (2)��167-177.
[35] MULLER R H�� SHEGOKAR R�� KECK C M. 20 Years of lipid nanoparticles (SLN & NLC)��Present state of development & industrial applications [J]. Curr Drug Discov Technol�� 2011�� 8(3)��207-227.
[36] ALI H�� EL-SAYED K�� SYLVESTER P W�� et al. Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles��evidence studies by Differential Scanning Calorimetry (DSC) and proton nuclear magnetic resonance spectroscopy (1H-NMR)[J]. Colloids Surf B Biointerfaces�� 2010�� 77(2)��286-289.
[37] FANG J Y�� FANG C L�� LIU C H��et al. Lipid nanoparticles as vehicles for topical psoralen delivery��Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)[J]. Eur J Pharm Biopharm�� 2008�� 70(2)��633-640.
[38] WANG J J�� LIU K S�� SUNG K C��et al. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection[J]. Eur J Pharm Sci�� 2009�� 38(2)��138-146.
[39] HU F Q�� JIANG S P�� DU Y Z�� et al. Preparation and characteristics of monostearin nanostructured lipid carriers[J]. Int J Pharm�� 2006�� 314(1)��83-89.
[40] FREITAS C�� MULLER R H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLNTM) dispersions [J]. Int J Pharm�� 1998��168(2)��221-229.
[41] HAN F�� LI S�� YIN R��et al. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system��Nanostructured lipid carriers[J]. Colloids and Surfaces A��Physicochem Eng Aspects�� 2008��315(1-3)��210-216.
[42] OBEIDAT W M�� SCHWABE K�� MULLER R H��et al. Preservation of nanostructured lipid carriers (NLC)[J]. Eur J Pharm Biopharm�� 2010�� 76(1)��56-67.
[43] SOUTO E B�� WISSING S A�� BARBOSA C M��et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery [J]. Int J Pharm�� 2004�� 278(1)��71-77.
[44] MITRIA K�� SHEGOKARA R�� GOHLAC S�� et al. Lipid nanocarriers for dermal delivery of lutein��Preparation�� characterization�� stability and performance [J]. Int J Pharm�� 2011��414(1-2)��267- 275.
[45] TIYABOONCHI W�� TUNGPRADIT W�� PLIANBANGCHANG P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles[J]. Int J Pharm�� 2007�� 337(1-2)��299-306.
[46] TEERANACHAIDEEKUL V�� MULLER R H�� JUNYAPRASERT V B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers(NLC)—Effects of formulation parameters on physicochemical stability[J]. Int J Pharm�� 2007��340(1-2)��198-206.
[47] MEI X G. Microcarries Drug Delivery System��΢����ҩ�����ϵͳ��[M]. Wuhan�� Huazhong University of Science & Technology Press��2009��21-22.
[48] JENSEN L B�� MAGNUSSSON E�� GUNNARSSON L�� et al. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles [J]. Int J Pharm�� 2010�� 390(1)��53-60.
[49] PAOLICELLE P�� CERRETO F�� CESA S�� et al. Influence of the formulation components on the properties of the system SLN-dextran hydrogel for the modified release of drugs[J]. J Microencapsulation�� 2009�� 26(4)��355-364.
[50] ABDEL-MOTTALEB M M A�� NEUMANN D�� LAMPRECHT A . In vitro drug release mechanism from lipid nanocapsules (LNC)[J]. Int J Pharm�� 2010�� 390(2)��208-213.
[51] POPLE P V�� SINGH K K. Development and evaluation of colloidal modified nanolipid carrier��Application to topical delivery of tacrolimus[J]. Eur J Pharm Biopharm�� 2011�� 79(1)��82-94.
[52] SOUZA L G�� SILVA E J�� MARTINS A L L��et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release[J]. Eur J Pharm Biopharm�� 2011�� 79(1)��189-196.
[53] ZHUANG C Y�� LI N�� WANG M��et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability[J]. Int J Pharm�� 2010�� 394(1-2)��179-185.
[54] PALIWAL R�� RAI S�� VAIDYA B�� et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery[J]. Nanomedicine�� 2009�� 5(2)��184-191.
[55] MULLER R H�� RUNGE S�� RAVELLI V�� et al. Oral bioavailability of cyclosporine��solid lipid nanoparticles (SLN_) versus drug nanocrystals[J]. Int J Pharm�� 2006�� 317(1)��82-89.
[56] GARCIA-FUENTES M�� PREGO C�� TORRES D�� et al. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery[J]. Eur J Pharm Sci�� 2005�� 25(1)��133-143.
[57] LUO Y F�� CHEN D W�� REN L X�� et al. Solid lipid nanoparticles for enhancing vinpocetine′s oral bioavailability[J]. J Controlled Release�� 2006�� 114(1)��53-59.
[58] MARCATO P D�� DURAN N. New aspects of nanopharmaceutical delivery systems[J]. J Nanosci Nanotechnol�� 2008�� 8(5)��2216-2229.
[59] KUMAR V V�� CHANDRASEKAR D�� RAMAKRISHNA S�� et al. Development and evaluation of nitrendipine loaded solid lipid nanoparticles��Influence of wax and glyceride lipids on plasma pharmacokinetics[J]. Int J Pharm�� 2007�� 335(1-2)��167-175.
[60] SCHOLER N�� HAHN H�� MULLER R H�� et al. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages[J]. Int J Pharm�� 2002�� 231(2)��167-176.
[61] KONTUSH A�� CHAPMAN M J. Functionally defective high-density lipoprotein��a new therapeutic target at the crossroads of dyslipidemia�� inflammation�� and atherosclerosis[J]. Pharmacol Rev�� 2006�� 58(3)��342-374.
[62] JOSHI M�� PATHAK S �� SHARMA S �� et al. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of Artemether��nanoject[J]. Int J Pharm�� 2008�� 364(1)��119-126.
[63] BUNJES H �� KOCH M H J�� WESTESEN K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles [J]. J Pharm Sci�� 2003�� 92(7)��1509-1520.
[64] SCHUBERT M A�� MULLER-GOYMANN C C. Characterisation of surface-modified solid lipid nanoparticles (SLN)��Influence of lecithin and nonionic emulsifier [J]. Eur J Pharm Biopharm�� 2005�� 61(1-2)��77-86.
[65] PARDEIKE J�� HOMMOSS A�� MULLER R H. Lipid nanoparticles (SLN�� NLC) in cosmetic and pharmaceutical dermal products [J]. Int J Pharm�� 2009��366(1-2)��170-184.
[66] ZHANG T C�� CHEN J N�� ZHANG Y�� et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide [J]. Eur J Pharm Sci�� 2011�� 43(3)��174-179.
[67] JIA L J�� ZHANG D R�� LI Z Y�� et al. Nanostructured lipid carriers for parenteral delivery of silybin��Biodistribution and pharmacokinetic studies[J]. Colloids Surf B Biointerfaces�� 2010��80(2)��213-218.
[68] SHEN J�� WANG Y�� PING Q E�� et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery[J]. J Controlled Release�� 2009��137(3)��217-223.
[69] PATLOLLA R R�� CHOUGULE M�� PATEL A R��et al. Formulation�� characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers[J]. J Controlled Release�� 2010�� 144(2)��233-241.
[70] XIANG Q Y�� WANG M T�� CHEN F��et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles[J]. Arch Pharm Res�� 2007�� 30(4)��519-525.
[71] PARDEIKE J�� SCHWABE K�� MULLER R H. Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect [J]. Int J Pharm�� 2010�� 396(1-2)��166-173.
[72] SOUTO E B�� WISSING S A�� BARBOSA C M�� et al. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations[J]. Eur J Pharm Biopharm�� 2004�� 58(1)��83-90.
[73] JOSHI M D�� MULLER R H. Lipid nanoparticles for parenteral delivery of actives [J]. Eur J Pharm Biopharm�� 2009��71(2)��161-172.
[74] MULLER R H�� KECK C M. Challenges and solutions for the delivery of biotech drugs-areview of drug nanocrystal technology and lipid nanoparticles[J]. J Biotechnol�� 2004�� 113(1-3)��151-170.
[75] ZHANG X G�� MIAO J�� DAI Y Q��et al. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells [J]. Int J Pharm�� 2008�� 361(1-2)��239-244.
[76] TRUJILLO C C�� WRIGHT A J. Properties and stability of solid lipid particle dispersions based on Canola Stearin and Poloxamer 188[J]. J Am Oil Chem Soc�� 2010�� 87(7)��715-730.
[77] KOVACEVIC A�� SAVIC S�� VULETA G�� et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC)��effects on size�� physical stability and particle matrix structure [J]. Int J Pharm�� 2011�� 406(1-2)��163-172.
[78] BUNJES H B�� KOCH M H J. Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles[J]. J Controlled Release�� 2005�� 107(2)��229-243.
[79] MULLER R H�� JACOBS C. Buparvaquone mucoadhesive nanosuspension��preparation�� optimisation and long-term stability[J]. Int J Pharm�� 2002�� 237(1-2)��151-161.
[80] MULLER R H�� JACOBS C�� KAYSER O. Nanosuspensions as particulate drug formulations in therapy��rationale for development and what we can expect for the future[J]. Adv Drug Deliv Rev�� 2001�� 47(1)��3-19.
[1] Ф���� ���� ��� ƽ���� ��־�� .������A��������֬��������Ʊ�������[J]. �й�ҩѧ��־, 2012,47(5): 362-366
[2] Ф�����������࣬ƽ���ܣ���־��.������A����𤸽������֬��������Ʊ����ڼ����۲���֯�ֲ��о�[J]. �й�ҩѧ��־, 2012,47(15): 1227-1232
[3] ���� κ��� �κø� ����԰ �Ž�ǿ ���°�.����������֬�����������Ʊ������󾭱�ǻ��ҩ��ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2011,46(1): 44-47
[4] ���� �߽��� ����Ȩ ��� Ҧ��.����֬���������˷�������ҩ��ҩ���о���չ[J]. �й�ҩѧ��־, 2010,45(6): 401-403
[5] ��ͩ�� ��԰ �ֻ��� ���� �˺� ����� ���ú�.��ѹ���ȷ��Ʊ���������ڼ��ع���֬���������Ĺ����о�[J]. �й�ҩѧ��־, 2010,45(6): 440-443
[6] ����֥;���;֣����;�����;�ϵ���;�����.Ҷ�����������-���ϩ����֬�����������Ʊ�����������ڷֲ�[J]. �й�ҩѧ��־, 2009,44(12): 920-925
[7] �Ѿ�;���ҹ�;����ƽ;����ΰ;����ǿ;������.���¸�Τ������֬�����������⿹����ҩЧ�о�[J]. �й�ҩѧ��־, 2009,44(11): 853-856
[8] ������;����;����;������;�´�Ϊ.�ڷ��۲��ع���֬���������Ƽ�ѧ��ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2009,44(06): 448-451
[9] �����;����;����;����;�ᄃ��;����.��ɼ������֬�������������ʵIJⶨ[J]. �й�ҩѧ��־, 2008,43(21): 1665-1668
[10] ����ϲ;Ҷ��ʤ;����;����;�﷼.�����ӹ���֬��������/pDNA��Ԫ������ij����о�[J]. �й�ҩѧ��־, 2008,43(14): 1050-1055
[11] ���ĸ�;����;���;����Ӣ;����Դ;��־��.��Ī��ƽ����֬�����������Ʊ���������͸Ƥ�����о�[J]. �й�ҩѧ��־, 2008,43(08): 598-605
[12] �����;�Թ�ϲ;ףΰΰ;�����;������.��Ƥ�ع���֬�����������Ʊ���С��ڷ������о�[J]. �й�ҩѧ��־, 2008,43(06): 435-438
[13] ����;���ػ�;������;��ѧ��;���Ӣ.�ΰ��򰢿���ù��A����֬���������������켰���ڷֲ��о�[J]. �й�ҩѧ��־, 2008,43(06): 431-434
[14] Ҷ��ʤ;����;����;�ƹ�;�﷼.���㾫����-pDNA���������֬���������ij����о�[J]. �й�ҩѧ��־, 2007,42(21): 1644-1648
[15] ������;�ƹ�;����;�����;�˼ͷ�.��Ī�򰷹���֬���������ڶ�������ҩ��ѧ����֯�ֲ��о�[J]. �й�ҩѧ��־, 2007,42(21): 1655-1659
Copyright 2010 by �й�ҩѧ��־